LB Pharmaceuticals (LBRX) Financials: Revenue & Earnings
LBRX$40.09+0.45 +1.12%
$1.29B
Market Cap
—
P/E
—
Forward P/E
—
Score
LB Pharmaceuticals (LBRX) Financials: Revenue & Earnings
LBRX price $40.09 +0.45 +1.12%
- Ticker
- LBRX
- Price
- $40.09
- Change
- +0.45 +1.12%
- Market cap ?
- $1.29B
- Beta ?
- 0.42
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
LBRX fair value Not meaningful. Price $40.09.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | -1.62 | — | — |
| 2026-08-11 | -1.71 | -0.80 | — | — |
| 2026-05-12 | -0.67 | -0.75 | — | — |
| 2026-03-26 | -0.45 | -0.45 | — | — |
| 2025-11-06 | -0.61 | -0.57 | — | — |
| 2025-09-08 | -1.44 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Miller Joseph M | Buy | 200.00K | $37.22 | 7.44M |
| 2026-10-09 | Kozauer Susan Gani | Buy | 200.00K | $37.22 | 7.44M |
| 2026-09-14 | Kozauer Susan Gani | Other | 0 | — | — |
| 2026-09-02 | Miller Joseph M | Other | 0 | — | — |
| 2026-07-30 | Deep Track Biotechnology Master Fund, Ltd. | Buy | 286.20K | $0.00 | 29 |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 117, holders +40 vs prior quarter. Ownership 106.06%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| DEEP TRACK CAPITAL, LP | 3.35M | 0 | 0.00% | 108.82M |
| BLACKROCK, INC. | 2.73M | 263.46K | +10.66% | 88.74M |
| RA CAPITAL MANAGEMENT, L.P. | 2.21M | 0 | 0.00% | 71.68M |
| TRAILS EDGE CAPITAL PARTNERS, LP | 1.52M | 203.66K | +15.44% | 49.43M |
| JPMORGAN CHASE & CO | 1.50M | 69.72K | +4.88% | 48.87M |
| COMMODORE CAPITAL LP | 1.50M | 0 | 0.00% | 48.68M |
| TCG CROSSOVER MANAGEMENT, LLC | 1.45M | -392.18K | -21.32% | 46.97M |
| CALIGAN PARTNERS LP | 1.44M | 0 | 0.00% | 46.67M |
| SPRUCE STREET CAPITAL LP | 1.38M | 0 | 0.00% | 44.66M |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 1.05M | 0 | 0.00% | 34.17M |
| VANGUARD CAPITAL MANAGEMENT LLC | 971.16K | 76.51K | +8.55% | 31.52M |
| BALYASNY ASSET MANAGEMENT L.P. | 921.47K | -2.22K | -0.24% | 29.91M |
| ALYESKA INVESTMENT GROUP, L.P. | 863.95K | 0 | 0.00% | 28.04M |
| VIVO CAPITAL, LLC | 800.00K | 0 | 0.00% | 25.96M |
| NAN FUNG GROUP HOLDINGS LTD | 630.66K | 0 | 0.00% | 20.47M |
| GEODE CAPITAL MANAGEMENT, LLC | 612.79K | 94.56K | +18.25% | 19.89M |
| STATE STREET CORP | 602.03K | 97.66K | +19.36% | 19.54M |
| LOGOS GLOBAL MANAGEMENT LP | 585.00K | -330.00K | -36.07% | 18.99M |
| GOLDMAN SACHS GROUP INC | 576.46K | 212.66K | +58.45% | 18.71M |
| JENNISON ASSOCIATES LLC | 540.90K | 2.69K | +0.50% | 17.55M |
| GREAT POINT PARTNERS LLC | 317.22K | 17.22K | +5.74% | 10.30M |
| BOOTHBAY FUND MANAGEMENT, LLC | 275.68K | 275.68K | New | 8.95M |
| MILLENNIUM MANAGEMENT LLC | 259.22K | 122.25K | +89.26% | 8.41M |
| AMERIPRISE FINANCIAL INC | 227.49K | 119.18K | +110.04% | 7.38M |
| CITADEL ADVISORS LLC | 215.97K | -200.94K | -48.20% | 7.01M |
Earnings and financials
LB Pharmaceuticals Inc Common Stock (LBRX) trades at $40.09, with a market cap of $1.29B and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn